TCL1A anticorps (PE)

N° du produit ABIN2663891

Cet anticorps anti-TCL1A Monoclonal Souris conjugué à PE (Clone 1-21) (ABIN2663891) détecte spécifiquement TCL1A dans FACS. L’anticorps est réactif avec des échantillons de Humain.

Aperçu rapide pour TCL1A anticorps (PE) (ABIN2663891)

Antigène: TCL1A (T-Cell Leukemia/lymphoma 1A (TCL1A))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp TCL1A est conjugé à/à la PE

Application: Flow Cytometry (FACS)

Clone: 1-21

Détail du produit anti-TCL1A anticorps (PE)

Purification: The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions. The solution is free of unconjugated PE and unconjugated antibody.

Isotype: IgG2b kappa

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide and 0.2 % (w/v) BSA .

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Protect from prolonged exposure to light. Do not freeze.

Stock: 4 °C

Stockage commentaire: The antibody solution should be stored undiluted between 2°C and 8°C.

Détails sur TCL1A

Antigène: TCL1A (T-Cell Leukemia/lymphoma 1A (TCL1A))

Autre désignation: TCL1

Sujet: TCL1, also known as T-cell leukemia/lymphoma protein 1A, protein p14 TCL1 and oncogene TCL-1, is a 14kD beta-barrel protein that was originally identified on the basis of its association with T-cell prolymphocytic leukemia (T-PLL). Activated by the T-cell receptor enhancer through inv(14)(q11,q32.1) or t(14,14)(q11,q32.1), TCL1 is normally expressed in immature cortical thymocytes, activated peripheral T-cells, pro-B cells, and naive mantle zone B cells of peripheral lymphoid tissues, but not in post-germinal center (GC) memory B cells and plasma cells. Akt and TCL1 interact via Akt's pleckstrin homology domain to form hetero-oligomers at the leaflet of the inner plasma membrane stimulating the protein kinase C-mitogen activated protein kinase-extracellular signal-related kinase (PKC-MAPK-ERK) signal transduction pathway. TCL1 also inhibits activation-induced cell death in T-cells by blocking PKCθ. In addition to T-PLL dysregulation is implicated in such B-cell neoplasias as lymphoblastic lymphoma, chronic lymphocytic leukemia (CLL) and Burkitt lymphoma.

Pathways: Stem Cell Maintenance